Dr Rajeev Jayadevan explains why a vaccine created for one Ebola strain may not necessarily protect against another and why ...

Moderna (NasdaqGS:MRNA) has expanded its collaboration with CEPI to accelerate development of an mRNA vaccine targeting ...

The new Ebola outbreak highlights market failures that hinder vaccine research and response to neglected tropical diseases.

The vaccine was pioneered by S. Korea, while collaboration between Korea University & Moderna since 2023 has only been ...

President Donald Trump is giving his endorsement to a January study by the Department of Health and Human Services that calls for cutting the number of vaccines recommended for every American ...

Since 2023, Moderna and Korea University have been developing a new mRNA vaccine for hantavirus. The work has been promising so far, but a finished product isn't likely coming any time soon.

Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody adintrevimab from the EVADE study, demonstrating minimal tolerability issues; Re ...

TEMPO.CO, Jakarta - On May 9, 2026, an Instagram account [archive] uploaded a video claiming that the hantavirus is the ...

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 ...

Several research groups and pharmaceutical companies had already been studying hantaviruses before the MV Hondius outbreak brought the disease into global headlines.

The WHO declared Ebola a Public Health Emergency of International Concern due to the Bundibugyo strain.

Collaboration Leverages Prior Andes, Marburg and Ebola Virus Research and Dyadic’s C1 Platform Capabilities for Fast, ...